We are committed to bring first-in-class breakthrough therapies to patients suffering from osteoarthritis in the world.
Nearly one out of two adults will be affected by osteoarthritis in their lifetime, making osteoarthritis the leading cause of disability in the world.
4Moving Biotech's team is developing 4P004, a disease-modifying osteoarthritis drug (DMOAD) candidate, a potential long-term solution for osteoarthritis patients.
4Moving Biotech at EULAR 2021
The OA-BIO European Consortium
4Moving Biotech announces a closing of €2M